Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Mirum Pharmaceuticals Inc (NASDAQ: MIRM) closed at $70.01 down -4.16% from its previous closing price of $73.05. In other words, the price has decreased by -$4.16 from its previous closing price. On the day, 0.93 million shares were traded. MIRM stock price reached its highest trading level at $74.9599 during the session, while it also had its lowest trading level at $68.6.
Ratios:
For a deeper understanding of Mirum Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.58 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 81.18. For the most recent quarter (mrq), Quick Ratio is recorded 3.16 and its Current Ratio is at 3.31. In the meantime, Its Debt-to-Equity ratio is 1.09 whereas as Long-Term Debt/Eq ratio is at 1.08.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 01 ’25 when MICHAEL GREY bought 50,000 shares for $74.00 per share.
GREY MICHAEL G sold 50,000 shares of MIRM for $3,500,000 on Nov 21 ’25. The Director now owns 0 shares after completing the transaction at $70.00 per share. On Nov 21 ’25, another insider, MICHAEL GREY, who serves as the Director of the company, bought 50,000 shares for $70.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MIRM now has a Market Capitalization of 3598064384 and an Enterprise Value of 3541280000. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.63 while its Price-to-Book (P/B) ratio in mrq is 12.30. Its current Enterprise Value per Revenue stands at 7.506 whereas that against EBITDA is -201.61.
Stock Price History:
The Beta on a monthly basis for MIRM is 0.42, which has changed by 0.6025008 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, MIRM has reached a high of $78.54, while it has fallen to a 52-week low of $36.88. The 50-Day Moving Average of the stock is -2.52%, while the 200-Day Moving Average is calculated to be 23.21%.
Shares Statistics:
For the past three months, MIRM has traded an average of 641.51K shares per day and 419220 over the past ten days. A total of 51.31M shares are outstanding, with a floating share count of 42.04M. Insiders hold about 18.20% of the company’s shares, while institutions hold 96.10% stake in the company. Shares short for MIRM as of 1763078400 were 7661323 with a Short Ratio of 11.94, compared to 1760486400 on 7389080. Therefore, it implies a Short% of Shares Outstanding of 7661323 and a Short% of Float of 14.91.
Earnings Estimates
The stock of Mirum Pharmaceuticals Inc (MIRM) is currently in the spotlight, with 6.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.03, with high estimates of $0.08 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.18 and -$0.54 for the fiscal current year, implying an average EPS of -$0.39. EPS for the following year is $0.38, with 7.0 analysts recommending between $0.97 and -$0.1.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $135.72M this quarter.It ranges from a high estimate of $138.6M to a low estimate of $131M. As of. The current estimate, Mirum Pharmaceuticals Inc’s year-ago sales were $99.41MFor the next quarter, 8 analysts are estimating revenue of $141.61M. There is a high estimate of $148.98M for the next quarter, whereas the lowest estimate is $137.89M.
A total of 9 analysts have provided revenue estimates for MIRM’s current fiscal year. The highest revenue estimate was $511M, while the lowest revenue estimate was $504M, resulting in an average revenue estimate of $507.91M. In the same quarter a year ago, actual revenue was $336.89MBased on 9 analysts’ estimates, the company’s revenue will be $609.04M in the next fiscal year. The high estimate is $659.61M and the low estimate is $574.1M.
